Hepion Pharmaceuticals Inc logo

Hepion Pharmaceuticals Inc

2
NAS:HEPA (USA)  
$ 2.45 -0.01 (-0.4%) 11:08 PM EST
At Loss
P/B:
0.66
Market Cap:
$ 10.63M
Enterprise V:
$ -7.20M
Volume:
20.87K
Avg Vol (2M):
91.70K
Also Trade In:
Volume:
20.87K
At Loss
Avg Vol (2M):
91.70K

Business Description

Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Name Current Vs Industry Vs History
Cash-To-Debt 80.02
Equity-to-Asset 0.65
Debt-to-Equity 0.02
Debt-to-EBITDA -0.01
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 68.58
9-Day RSI 59.12
14-Day RSI 55.21
6-1 Month Momentum % -43.03
12-1 Month Momentum % -79.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.32
Quick Ratio 3.32
Cash Ratio 3.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -172.7
Shareholder Yield % 0.63
Name Current Vs Industry Vs History
ROE % -118.32
ROA % -92.72
ROIC % -798.38
ROC (Joel Greenblatt) % -33997.93
ROCE % -122.04

Financials (Next Earnings Date:2024-05-10 Est.)

HEPA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:HEPA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Hepion Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -12.42
Beta 1.67
Volatility % 90.76
14-Day RSI 55.21
14-Day ATR ($) 0.289018
20-Day SMA ($) 2.3595
12-1 Month Momentum % -79.71
52-Week Range ($) 1.49 - 20.66
Shares Outstanding (Mil) 4.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Hepion Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Hepion Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Hepion Pharmaceuticals Inc Frequently Asked Questions

What is Hepion Pharmaceuticals Inc(HEPA)'s stock price today?
The current price of HEPA is $2.45. The 52 week high of HEPA is $20.66 and 52 week low is $1.49.
When is next earnings date of Hepion Pharmaceuticals Inc(HEPA)?
The next earnings date of Hepion Pharmaceuticals Inc(HEPA) is 2024-05-10 Est..
Does Hepion Pharmaceuticals Inc(HEPA) pay dividends? If so, how much?
Hepion Pharmaceuticals Inc(HEPA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1